Global Narcolepsy Therapeutics Market 2023-2029

March 2023 | 63 pages | ID: GC1F3D4FF7E4EN
Gen Consulting Company

Abstracts

Narcolepsy is a chronic neurological disorder that affects the ability to regulate sleep-wake cycles. It is characterized by excessive daytime sleepiness, sudden episodes of muscle weakness or paralysis (cataplexy), hallucinations, and disrupted nighttime sleep. The most common medications used to manage narcolepsy symptoms include stimulants, such as modafinil and armodafinil, which promote wakefulness, and antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), which can help reduce muscle weakness and improve mood. Other medications, such as sodium oxybate, may be prescribed for the treatment of cataplexy. In 2022, the global narcolepsy therapeutics market stood at USD 1,048.0 million. Recording a CAGR of 16.91% from 2023 to 2029, the worth is projected to reach ~USD 3,128.4 million by 2029, according to the latest market data.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global narcolepsy therapeutics market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the indication, product, therapeutics, and region. The global market for narcolepsy therapeutics can be segmented by indication: type 1 narcolepsy, type 2 narcolepsy, secondary narcolepsy. Among these, the type 1 narcolepsy segment was accounted for the highest revenue generator in 2022. Narcolepsy therapeutics market is further segmented by product: commercialized products, pipeline products. The commercialized products segment is estimated to account for the largest share of the global narcolepsy therapeutics market. Based on therapeutics, the narcolepsy therapeutics market is segmented into: central nervous system stimulants, norepinephrine reuptake inhibitor, histamine-3 (H3) receptor antagonist/inverse agonist. The central nervous system stimulants segment held the largest share of the global narcolepsy therapeutics market in 2022 and is anticipated to hold its share during the forecast period. On the basis of region, the narcolepsy therapeutics market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. In 2022, North America made up the largest share of revenue generated by the narcolepsy therapeutics market.

The commercialized products market is further segmented into Xywav, Sunosi, Wakix. The Xywav segment captured the largest share of the market in 2022 and is expected to maintain its dominance during the forecast period.

Market Segmentation
By indication: type 1 narcolepsy, type 2 narcolepsy, secondary narcolepsy
By product: commercialized products, pipeline products
By therapeutics: central nervous system stimulants, norepinephrine reuptake inhibitor, histamine-3 (H3) receptor antagonist/inverse agonist
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The market research report covers the analysis of key stake holders of the global narcolepsy therapeutics market. Some of the leading players profiled in the report include Avadel Pharmaceuticals plc, Axsome Therapeutics, Inc., Harmony Bioscience, LLC, Jazz Pharmaceuticals plc, NLS Pharmaceutics AG, Sumitomo Pharma Co., Ltd., Suven Life Sciences Limited, Takeda Pharmaceutical Co., Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
To analyze and forecast the market size of the global narcolepsy therapeutics market.
To classify and forecast the global narcolepsy therapeutics market based on indication, product, therapeutics, region.
To identify drivers and challenges for the global narcolepsy therapeutics market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global narcolepsy therapeutics market.
To identify and analyze the profile of leading players operating in the global narcolepsy therapeutics market.

Why Choose This Report
Gain a reliable outlook of the global narcolepsy therapeutics market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY INDICATION

Type 1 narcolepsy
Type 2 narcolepsy
Secondary narcolepsy

PART 6. MARKET BREAKDOWN BY PRODUCT

Commercialized products
Pipeline products

PART 7. MARKET BREAKDOWN BY THERAPEUTICS

Central nervous system stimulants
Norepinephrine reuptake inhibitor
Histamine-3 (H3) receptor antagonist/inverse agonist

PART 8. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 9. KEY COMPANIES

Avadel Pharmaceuticals plc
Axsome Therapeutics, Inc.
Harmony Bioscience, LLC
Jazz Pharmaceuticals plc
NLS Pharmaceutics AG
Sumitomo Pharma Co., Ltd.
Suven Life Sciences Limited
Takeda Pharmaceutical Co., Ltd.

DISCLAIMER